Iovance Biotherapeutics' strong Q3 earnings and promising drug pipeline suggest growth potential for risk-tolerant investors.

Replimune Group Inc的股价已达到新的52周高点，股价触及12.86美元。这一里程碑反映了这家专注于溶瘤免疫疗法的生物技术公司的显著上升趋势。在过去一年中，Replimune的股票价值增长了13.23%，表明公司业绩强劲，投资者对公司前景的信心不断增强。达到这个52周高点是Replimune财务历程中的一个重要亮点，因为公司继续推进其临床项目并扩大市场份额。

Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to ...

In fact, Property Share is the first entity to be granted an SM REIT licence by Sebi. Infrastructure and real estate firm ...

Priced at £14,995 excluding VAT, this commercial vehicle will bring business users affordability into the EV sector. Dacia has unveiled Britain’s cheapest new van with its Spring Cargo. To make this ...